title: Essential requirement for PP2A inhibition by the oncogenic receptor c-KIT suggests PP2A reactivation as a strategy to treat c-KIT+ cancers -- Letter.
authors.forename: Amaury G
authors.initials: AG
authors.lastname: Dumont
authors.forename: David G
authors.initials: DG
authors.lastname: Reynoso
authors.forename: Jonathan C
authors.initials: JC
authors.lastname: Trent
mesh_terms: D000818:Animals; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects*; D004789:Enzyme Activation / Q000187:drug effects; D000068876:Fingolimod Hydrochloride; D046152:Gastrointestinal Stromal Tumors / Q000188:drug therapy / Q000235:genetics / Q000473:pathology; D006801:Humans; D007166:Immunosuppressive Agents / Q000494:pharmacology; D020128:Inhibitory Concentration 50; D051379:Mice; D009154:Mutation; D011409:Propylene Glycols / Q000494:pharmacology*; D054648:Protein Phosphatase 2 / Q000235:genetics / Q000378:metabolism; D019009:Proto-Oncogene Proteins c-kit / Q000235:genetics / Q000378:metabolism; D013110:Sphingosine / Q000031:analogs & derivatives* / Q000494:pharmacology
chemical_list: D007166:Immunosuppressive Agents; D011409:Propylene Glycols; D019009:Proto-Oncogene Proteins c-kit; D054648:Protein Phosphatase 2; D000068876:Fingolimod Hydrochloride; D013110:Sphingosine